Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

NCT07047586 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

146

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)

Interventions

DRUG: Tislelizumab
DRUG: Lenvatinib

Sponsor

Fudan University